Protalix BioTherapeutics
PLX
66 hedge funds and large institutions have $6.6M invested in Protalix BioTherapeutics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 12 increasing their positions, 16 reducing their positions, and 23 closing their positions.
2,400% more call options, than puts
Call options by funds: $125K | Put options by funds: $5K
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
5% more funds holding
Funds holding: 63 → 66 (+3)
5.16% less ownership
Funds ownership: 12.85% → 7.69% (-5.2%)
25% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 16
45% less capital invested
Capital invested by funds: $11.9M → $6.6M (-$5.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$946K |
| 2 |
Goldman Sachs
New York
|
+$437K |
| 3 |
Jane Street
New York
|
+$309K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$187K |
| 5 |
CC
Centiva Capital
New York
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.52M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.04M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$950K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$416K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$342K |
PLX Hedge Fund Activity: Q2 2024 in Review
66 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2024, worth a combined $6.6M — down 45% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PLX positions and 23 closed out — a net gain of 4 holders — while 12 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, adding an estimated $946K. The largest seller was BlackRock, cutting an estimated $3.52M.
- 66 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2024, up from 63 in Q1 2024.
- Funds reported $6.6M of Protalix BioTherapeutics stock for Q2 2024, down 45% quarter-over-quarter.
- 27 funds opened new Protalix BioTherapeutics positions in Q2 2024 and 23 closed out, a net change of +4 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2024 was Millennium Management, an estimated $946K added.
- The largest Protalix BioTherapeutics seller in Q2 2024 was BlackRock, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2024.